ENSC - Ensysce Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

2.3600

-0.0800

(-3.28%)

At close: 04:00PM EDT

2.4000

+0.04

(+1.69%)

After hours:

07:37PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

MACD

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	2.4400
Open	2.4000
Bid	2.3400 x 900
Ask	2.4300 x 1100
Day's Range	2.3401 - 2.4576
52 Week Range	2.2800 - 220.8000
Volume	33,837
Avg. Volume	681,532

Market Cap	3.855M
Beta (5Y Monthly)	0.58
PE Ratio (TTM)	N/A
EPS (TTM)	-126.8600
Earnings Date	Mar 30, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	16.39

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ENSC

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

Zacks Small Cap Research
ENSC: ENSC Provides an Attractive Entry Point
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) has been one of the companies that we cover that we believe most of America is hoping is successful. The opioid crisis remains a plague on the American public and is destroying families and whole communities. The National Institute on Drug Abuse reported more than 106,000 overdose deaths in
ACCESSWIRE
Ensysce Biosciences Reports First Quarter 2023 Financial Results
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today reported financial results for the first quarter of 2023 following the recently completed, successful PF614-MPAR-101 study.
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $7 Million Public Offering
/ Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today the closing of the previously announced public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,800,876 shares of common stock and Series A-2 warrants
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Pricing of $7 Million Public Offering
/ Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, announced today announced the pricing of a public offering of an aggregate of 1,800,876 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,800,876 shares of common stock and Series A-2 warrants to purchase
Benzinga
Why Are Ensysce Biosciences Shares Are Trading Higher Today
Ensysce Biosciences Inc (NASDAQ: ENSC) completed PF614-MPAR-101, a clinical study examining the company's first pain medication with overdose protection, PF614-MPAR. The final Part B of the study examined dose escalation of PF614-MPAR from 25 to 200 mg (1 to 8 dose units) and showed that PF614-MPAR reduced opioid delivery when three or more doses were consumed simultaneously. The company says that PF614-MPAR is the first drug that can limit opioid exposure when too many pills are swallowed, prot
ACCESSWIRE
Ensysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
Ensysce Biosciences, Inc. (NASDAQ:ENSC), clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced completion of PF614-MPAR-101, a clinical study examining the Company's first pain medication with overdose protection, PF614-MPAR.
Zacks Small Cap Research
ENSC: ENSC Announces Potential Game-Changing Results
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) has been one of the companies that we cover that we believe most of America is hoping is successful. The opioid crisis remains a plague on the American public and is destroying families and whole communities. The National Institute on Drug Abuse reported more than 106,000 overdose deaths in
Insider Monkey
10 Stocks Targeted By Short Sellers Recently
In this piece, we will take a look at ten stocks targeted by short sellers recently. For more stocks, head on over to 5 Stocks Targeted By Short Sellers Recently. A curious outcome of the turmoil ushered in by the coronavirus pandemic was the historic tussle between retail and institutional investors. The pandemic made major […]
ACCESSWIRE
Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Company's CEO, Dr. Lynn Kirkpatrick will be participating in ‘Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences Customer Case Study Demonstrating the Benefits of an Integrated Approach for Accelerating Development' today,
ACCESSWIRE
Ensysce Biosciences Announces Updated Investor Presentation Available Via Investor Relations Website
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced an updated investor presentation has been posted to the Company's investor relations website.
Zacks Small Cap Research
ENSC: Ensysce Provides Positive Result on Non-Addictive Opioid
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) has been one of the companies that we cover that we believe most of America is hoping is successful. The opioid crisis remains a plague on the American public and is destroying families and whole communities. The National Institute on Drug Abuse reported more than 106,000 overdose deaths in
ACCESSWIRE
Ensysce Biosciences Announces Positive Results from Oral Human Abuse Potential Trial for PF614
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), today announced positive results from a key study on the oral human abuse potential of PF614, a potential next generation pain medicine.
ACCESSWIRE
Ensysce Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today reported financial results for the fourth quarter and full year of 2022.
ACCESSWIRE
Ensysce Biosciences Announces Completion of Enrollment for Groundbreaking Opioid Overdose Protection Study
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced the completion of enrollment in the final stage of the Phase 1 study, PF614-MPAR-101.
Zacks Small Cap Research
ENSC: Tackling the Opioid Crisis
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) has been one of the companies that we cover that we believe most of America is hoping is successful. The opioid crisis remains a plague on the American public and is destroying families and whole communities. The National Institute on Drug Abuse reported more than 106,000 overdose deaths in
Insider Monkey
10 Penny Stocks with Insider Buying
In this piece, we will take a look at ten penny stocks with insider buying. For more penny stocks, head on over to 5 Penny Stocks with Insider Buying. With the first quarter of 2023 coming to an end, the stock market continues to be in a topsy-turvy environment. 2023 was off to a strong […]
ACCESSWIRE
Dr. Lynn Kirkpatrick, Featured Speaker to Discuss Ensysce Overdose Protection Platform at DCAT Seminar
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced Dr. Lynn Kirkpatrick, Chief Executive Officer, is a featured speaker at a lunch seminar on March 22, 2023 in New York sponsored by partner Quotient Sciences.
ACCESSWIRE
Ensysce Biosciences Announces Critical Step in Human Abuse Potential Study of PF614 With Database Lock
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced the database lock on February 24, 2023 for the oral Human Abuse Potential (HAP) study of PF614. PF614 is a TAAP™ (Trypsin Activated Abuse Protection) product to treat severe pain.
ACCESSWIRE
Ensysce Biosciences Provides Corporate Update
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today issued a letter to shareholders from Chief Executive Officer, Dr. Lynn Kirkpatrick, to address the Company's most recent frequently asked questions.
ACCESSWIRE
Ensysce Biosciences Receives Positive Nasdaq Listing Determination
Ensysce Biosciences, Inc. (the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that by decision dated February 14, 2023, a Nasdaq Hearings Panel (the "Panel") granted the Company's request for continued listing on The Nasdaq Stock Market ("Nasdaq"), subject to the Company evidencing compliance with all applicable criteria
ACCESSWIRE
Ensysce Biosciences to Present its Overdose Protection Program at the 4th Annual NIH 'HELPING END ADDICTION LONG-TERM' (HEAL) Meeting
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced a Poster Presentation will be presented by Geoff Birkett, Chief Commercial Officer of Ensysce, at the Annual NIH HEAL Meeting on February 22, 2023, in Washington, D.C.
ACCESSWIRE
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-market
Zacks Small Cap Research
ENSC: Ensysce Continues to Progress Toward Opioid Solution
By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) is committed to finding a solution to the opioid crisis plaguing the US and other developed countries around the world. Through its proprietary TAAP technology Ensysce is in the process of receiving approval for an abuse-resistant yet still pain-relieving opioid. The company continues to
ACCESSWIRE
Ensysce Biosciences, Inc. Announces $3 Million Registered Direct Offering
Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that it has entered into a definitive agreement for the purchase and sale of 3,571,431 shares of the Company's common stock at a purchase price of $0.84 per share of common stock in a registered direct offering priced at-the-marked under Nasdaq
ACCESSWIRE
Ensysce Biosciences Announces the Distribution of Series A Preferred Stock to Holders of Its Common Stock
Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety to reduce abuse and overdose, today announced that its Board of Directors has declared a dividend of 0.001 of a share of newly-designated Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company's common stock held of record